Latest Advances in Understanding Preeclampsia

By Christopher W. G. Redman, I. Sargent. Science, 2005

2,645 citations recorded by the source corpus.

Subfields: Immunology, Obstetrics and Gynecology, Public Health, Environmental and Occupational Health

View Paper: https://www.semanticscholar.org/paper/8559facb99a40750c443d1f7925eff62167fc17e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. L. Yeo
2. Roberto Romero
3. T. Chaiworapongsa
4. P. Chaemsaithong

In Obstetrics and Gynecology

1. J. Roberts
2. L. Yeo
3. Roberto Romero
4. T. Chaiworapongsa
5. C. Hubel
6. P. Chaemsaithong

In Public Health, Environmental and Occupational Health

1. J. Roberts
2. L. Yeo
3. Roberto Romero
4. T. Chaiworapongsa
5. Hyagriv Simhan
6. P. Chaemsaithong

Citations in the corpus

• Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin Summary, Number 222. (2020, background): “Several mechanisms of disease have been proposed in preeclampsia (1, 51, 52), including the following: chronic uteroplacental ischemia (53), immune maladaptation (53), very low-density lipoprotein toxicity (53), genetic imprinting (53), increased trophoblast apoptosis or necrosis (54, 55), and an ex”
• Soluble endoglin contributes to the pathogenesis of preeclampsia (2006, background): “Discussion Maternal endothelial dysfunction caused by placenta-derived soluble factors such as sFlt1 is emerging as a major component in the pathogenesis of preeclampsi”
• Pre-eclampsia part 1: current understanding of its pathophysiology (2014, positive): “Hypoxia-inducible factor-1 mediates the biological effects of oxygen on human trophoblast differentiation through TGFβ(3).”
• The Two Stage Model of Preeclampsia: Variations on the Theme (2008, background): “angiogenic factors [5], syncytiotrophoblast microparticles (STBM) [6] and formed blood products activated in the intervillus space [7].”